Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Lymphoma, Mantle-Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Graft vs Host Disease 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 15fludarabine phosphate 11fludarabine 11Whole-Body Irradiation 11Mycophenolic Acid 11Busulfan 9Melphalan 8Tacrolimus 7Peripheral Blood Stem Cell Transplantation 7Granulocyte Colony-Stimulating Factor 5Cyclosporine 5Azacitidine 5Filgrastim 4venetoclax 3Cord Blood Stem Cell Transplantation 3Biopsy 3thymoglobulin 2decitabine and cedazuridine drug combination 2Vorinostat 2Thiotepa 2Specimen Handling 2Sirolimus 2Rituximab 2Methotrexate 2Injections 2Hematopoietic Stem Cell Transplantation 2Etoposide 2Cytarabine 2Cyclosporins 2Clofarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia, Refractory, with Excess of Blasts × Calcineurin Inhibitors × 1 year × Clear all
NCT03320642 2025-10-21

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Incyte Corporation

Phase 1 Terminated
84 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡